Cho WK, et al. - In this multi-institutional study, researchers examined the impact of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). After neoadjuvant chemotherapy and breast-conserving surgery, patients with ypCR have good prognosis. Tumor bed boost in ypCR patients was not an important factor in local control and survival. In ypCR patients following NAC and BCT, the benefit of tumor bed boost might be minimal. In further study, the benefit of boosting the tumor bed in ypCR patient needs to be investigated.